Malaria vaccine
| Vaccine description | |
|---|---|
| Target | Malaria |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Mosquirix |
| Routes of administration | Intramuscular[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
A Malaria vaccine is a vaccine that prevents malaria, a mosquito-borne infectious disease which affected an estimated 249 million people globally in 85 malaria-endemic countries and areas and caused 608,000 deaths in 2022.[2] The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix.[1] As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission.[3] It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years.[4][5] The vaccine reduces hospital admissions from severe malaria by around 30%.[4]
Research continues with other malaria vaccines. The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy,[6][7] and only the second malaria vaccine to be recommended by the WHO.[8] In April 2023, Ghana's Food and Drugs Authority approved the use of the R21 vaccine for use in children aged between five months and three years old.[9] Following Ghana's decision, Nigeria provisionally approved the R21 vaccine.[10]
The malaria vaccine is on the World Health Organization's List of Essential Medicines.[11]
- ^ a b c Cite error: The named reference
EMA Mosquirixwas invoked but never defined (see the help page). - ^ World Malaria Report 2023 - World Health Organization. Switzerland: World Health Organization. 30 November 2023. ISBN 978-92-4-006489-8. Archived from the original on 27 July 2024. Retrieved 27 July 2024.
- ^ Cite error: The named reference
who-rtswas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
npr-052022was invoked but never defined (see the help page). - ^ World Health Organization (2022). "Malaria vaccine: WHO position paper – March 2022". Weekly Epidemiological Record. 97 (9): 60–78. hdl:10665/352337.
- ^ Cite error: The named reference
bbc-r21was invoked but never defined (see the help page). - ^ Cite error: The named reference
EurekAlert042021was invoked but never defined (see the help page). - ^ "WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization". 2 October 2023. Archived from the original on 3 October 2023. Retrieved 4 October 2023.
- ^ Cite error: The named reference
bbc-r21-202304was invoked but never defined (see the help page). - ^ "The country with the highest rate of malaria deaths in the world has approved Oxford's vaccine". Quartz. 18 April 2023. Archived from the original on 19 April 2023. Retrieved 19 April 2023.
- ^ World Health Organization (2025). The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. hdl:10665/382243.